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Abstract: Similarly to Epstein-Barr virus (EBV), the human herpesvirus-8 (HHV-8) is a γ-
herpesvirus, recently recognized to be associated with the occurrence of rare B cell lymphomas and 
atypical lymphoproliferations, especially in the human immunodeficiency virus (HIV) infected 
subjects. Moreover, the human herpesvirus-6 (HHV-6), a β-herpesvirus, has been shown to be 
implicated in some non-malignant lymph node proliferations, such as the Rosai Dorfman disease, 
and in a proportion of Hodgkin’s lymphoma cases. HHV-6 has a wide cellular tropism and it might 
play a role in the pathogenesis of a wide variety of human diseases, but given its ubiquity, disease 
associations are difficult to prove and its role in hematological malignancies is still controversial. 
The involvement of another β-herpesvirus, the human cytomegalovirus (HCMV), has not yet been 
proven in human cancer, even though recent findings have suggested its potential role in the 
development of CD4+ large granular lymphocyte (LGL) lymphocytosis. Here, we review the current 
knowledge on the pathogenetic role of HHV-8 and human β-herpesviruses in human 
lymphoproliferative disorders. 
 
Introduction. Epstein-Barr virus (EBV) is a γ-
herpesvirus well recognized to be involved in the 
development of human B and NK/T cell lymphomas, 
either in the general population or in the 
immunosuppressed individuals. EBV is a lympho- and 
epitheliotropic γ-herpesvirus apparently carried as an 
harmless passenger in the immunocompetent host. 
Alterations in the delicate balance between the virus 
and the host immune control may result in a wide range 
of EBV-associated diseases: the simplest scenario is 
the outgrowth of EBV-transformed B-lymphoblasts, 
expressing the full array of EBV latent gene (EBNA1, 
2, 3A, 3B, 3C, LP, LMP1 and LMP2) leading to the 
development of post-transplant lymphoproliferative 
disease (PTLD) in immunodeficient subjects. EBV is 
also associated to malignancies in immunocompetent 
hosts arising from either epithelial, T cell or B cell 
origin in which is present with a limited pattern of 
latency genes: latency II (expression of EBNA1, 
LMP2A) is typical of Nasopharingeal Carcinoma, 
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Gastric Carcinoma and Hodgkin’s Lymphoma; latency 
I (expression of EBNA1) is associated to the Burkitt 
Lymphoma.1 
In addition to EBV, another γ-herpesvirus, Kaposi’s 
sarcoma-associated herpesvirus (KSHV or HHV-8) is 
oncogenic. Among β-herpesviruses, several 
investigators have suggested that human herpesvirus-6 
(HHV-6) also may be an oncogenic virus. Here, we 
review the current knowledge on the pathogenetic role 
of human β-herpesviruses and HHV-8 in human 
lymphoproliferative disorders. 
 
β HERPESVIRUSES:  
HHV-6. Epidemiology and biology. HHV-6 was first 
isolated in 1986 and later two viral variants have been 
identified, namely HHV-6A and HHV-6B, showing an 
overall nucleotide sequence identity of 90%. HHV-6 is 
ubiquitous in human throughout the world, with 
seroconversion occurring early in life.2,3 Salivary 
contact is likely to be the vehicle for transmission, but 
intrauterine passage is also possible. HHV-6 can be 
transmitted by blood products and with bone marrow 
and solid organ transplantation. Through its cellular 
receptor CD46, an ubiquitary complement regulatory 
glycoprotein4, HHV-6 can primarily infect either early 
self-renewing bone marrow precursors or mature blood 
cells, as well as oropharinx/salivary glands, epithelial 
mucosa of female genital tract and brain tissue. 
Following primary infection, HHV-6 can persist 
lifelong mainly in monocytes and other peripheral 
blood mononuclear cells.3 Only rare cells remain 
latently infected in healthy individuals, as shown by 
PCR testing. Of note, HHV6, unique among all the 
herpesviruses, exhibits a particular form of persistence 
in the infected cell, consisting in the integration of the 
whole viral genome into host chromosomes. The 
prevalence of the ‘chromosomal integration of HHV-6’ 
(CIHHV-6) ranges from 0.2% to 3% among different 
geographical areas.5,6 It has been observed that the 
main route of acquisition of CIHHV-6 is the vertical 
transmission, which implies that at least one copy of 
viral DNA is present in all the nucleated cells of the 
host. The HHV-6 genome shows human telomere-like 
repeat sequences at both its ends and this may foster 
the viral integration in some preferred chromosomal 
regions (mainly 17p13.3, 22q13, 1q44), which are 
close to or within the telomeres.7-10 
HHV-6 has been demonstrated to efficiently 
replicate in vitro and cause a cytopathic effect either in 
CD4+ T lymphocytes or in thymocytes, inducing a 
suppression of T-cell functions. Cells transfected with 
HHV-6 can cause tumors in nude mice.11 However, the 
evidence linking HHV-6 to human hematological 
malignancies is circumstantial, and far from 
definitive.12 HHV-6 DNA can transform human 
epidermal keratinocytes and NIH 3T3 cells in vitro. 13-14 
HHV-6 has a number of unique genes that are plausible 
causes of oncogenesis. Its ORF-1 gene encodes a 
protein that is capable of transforming NIH 3T3 cells in 
vitro, and cells expressing ORF-1 protein produce 
fibrosarcomas when injected into nude mice.15 The 
ORF-1 protein appears to maintain the transformed 
state of tumor cells by binding p53 and thereby 
inhibiting its tumor suppressor properties.16 HHV-6 
also has a unique immediate early gene called U95 that 
has binding sites for nuclear factor-kappa B (NF-kB).17 
Dysregulation of NF-kB has been postulated to 
contribute to cancer, through its effects on both the 
proliferative and apoptotic pathways.18 (Table 1) 
 
Hodgkin’s disease. Reports differ as to the possible 
role of HHV-6 in Hodgkin’s disease (HD). Torelli et 
al.19 reported finding HHV-6 sequences by PCR in 3 of 
25 cases of HD, all nodular sclerosis type, and in none 
of 41 cases of non-Hodgkin’s lymphoma. Krueger et 
al.20 performed immunohistochemical studies of tumors 
from 103 patients with HD, and found tissue sections 
to be infected frequently by both EBV and HHV-6; 
lymphocytes and histiocytes were infected 
preferentially. Lacroix et al.21 found HHV-6 DNA 
more frequently in the nodular sclerosis form of HD: of 
73 patients with nodular sclerosis, 39 (49%) had both 
HHV-6 and EBV DNA, 25 (34%) had only HHV-6, 
and 8 (11%) had only EBV. In contrast, of 10 cases of 
the mixed cellularity form of HD, 4 (40%) had both 
viruses, 1 had HHV-6 only, 4 had EBV only, and 1 had 
neither. HHV-6+/EBV- patients were younger than the 
EBV+/HHV-6- patients and 92% of the HHV-6+ lymph 
nodes contained variant B. However, Luppi et al.22 
examined a large series of patients with HD in which 
HHV-6 DNA was found by both PCR and Southern 
blot analysis, did not detect either latent or lytic HHV-
6 antigens in neoplastic cells, and detected only limited 
expression in Reed–Sternberg cells. Thus, the role of 
HHV-6 in any form of HD remains unclear. Recently, 
Lacroix et al.23 showed the transforming, 
transactivating and oncogenic properties of HHV-6B 
and localized the transforming activity into DR7 gene. 
Cells expressing viral DR7 protein revealed 
tumorigenic properties when injected into nude mice. 
The expression of DR7B protein in Reed-Sternberg 
cells from HD patients causes molecular alterations 
into the cells typical of the lymphoproliferative 
disorder. In particular, the oncoprotein protects 
infected cells from apoptosis by retaining human p53 
within the cytoplasm and by increasing NF-kB cellular 
transcription factor. The action on NF-kB is mainly 
exerted through two mechanisms: the transactivation of 
the expression of its subunities p65 and p50-p105 and 
the direct interaction of DR7B with the assembled 
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protein. Lastly, DR7B promotes the overexpression of 
Id2, inhibitor of E2A transcription factor, that 
negatively regulates cell differentiation.23 Further 
studies are needed to confirm a plausible pathogenetic 
role of HHV-6 infection in HD.  
 
Non-Hodgkin’s lymphomas. Luppi et al.24 reported a 
higher frequency of HHV-6 DNA in a well-
characterized series of patients with 
angioimmunoblastic T-cell lymphoma (AITL), a 
subtype of T-cell non-Hodgkin’s lymphoma (NHL), 
compared with other lymphoma subtypes and controls. 
These findings have been confirmed by Zhou et al.25 
showing a clear association between histological 
progression of AITL and the detectable copy number 
of both EBV and HHV-6B in the AITL lesional tissue. 
While this increased viral load could reflect a role for 
HHV-6 in the pathogenesis and progression of AITL, it 
could also be the consequence of increasing 
dysfunction of the immune system during lymphoma 
progression. Immunohistochemical studies have so far 
failed to demonstrate HHV-6 antigens in the CD4+ T 
cells (the likely proliferating elements) within AITL 
lesions. 
 
Leukemias. Persistent IL-2-regulated HHV-6 infection 
of adult T-cell leukemia cells causes T-cell leukemia to 
progress more rapidly,26 but in vivo studies have not 
yet confirmed a pathogenetic role for HHV-6 in this 
disease. Few other studies aiming to investigate the 
association of HHV-6 with acute leukemia have been 
reported. The largest study showed significant higher 
titres of HHV-6 antibodies in patients with acute 
myeloid leukemia, but not with acute lymphoblastic 
leukemia.27 Salonen et al.28 found that 40% of children 
with leukemia had IgM antibodies to HHV-6 compared 
to 7.7% of age- and sex-matched children with various 
neurological diseases. However, molecular studies 
have so far failed to show a higher rate of HHV-6 DNA 
in peripheral blasts from children with acute 
lymphoblastic leukemia compared with healthy 
subjects.29 A recent report found higher rates of 
seropositivity to human cytomegalovirus (HCMV) 
among patients with B-cell chronic lymphocytic 
leukemia than among healthy control subjects, 
although restricted only to some geographical areas, 
but the same was not true for seropositivity to HHV-6 
(or EBV and HHV-7).30 In conclusion, with the 
possible exception of adult T-cell leukemia, available 
data do not lend support to a role for HHV-6 in human 
acute leukemias. 
 
Non-malignant lymphatic tissue proliferation. Of 
interest, HHV-6 late antigens have so far been detected 
only in non-malignant lymph node proliferations, 
namely in cases of reactive lymphadenitis,31, 32 in which 
HHV-6 antigens appear to be restricted to CD4+T 
cells. HHV-6 late antigens have also been identified in 
cases of Rosai Dorfman disease, otherwise known as 
sinus histiocytosis with massive lymphadenopathy, a 
benign chronic disease, mainly affecting children and 
young adults and with no progression to lymphoma. 
HHV-6 infection appears to be restricted to follicular 
dendritic cells and, more significantly, to the abnormal 
histiocytes that represent the proliferating elements and 
the hallmark of this disease.33 (Table 1) 
 
HCMV. Epidemiology and biology. HCMV was 
simultaneously isolated from salivary glands by Rowe 
and Smith in 1956. This virus was designated 
‘cytomegalovirus’ and the associated clinical syndrome 
was referred to as ‘cytomegalovirus inclusion disease’ 
because viral cytopathic effects typically result in cell 
swelling and intranuclear inclusions. 
HCMV infection is widespread in the entire human 
population, with prevalence increasing with age. In 
Western Countries, seropositivity rates range 40-70%, 
while in developing countries are much higher.34 Using 
PCR, CMV viremia has been detected in about 98% of 
healthy individuals over 50 years of age. HCMV can 
be transmitted orally, sexually, and parenterally; 
primary infection may be subclinical in healthy 
subjects. Even asymptomatic carriers may at times 
shed HCMV in urine and saliva.35-36 
HCMV productive infection (lytic cycle) is 
restricted to endothelial cells and fibroblasts, typically 
causing cell death and tissue damage in lung, liver, 
colon, brain and retina. Similarly to other 
herpesviruses, HCMV can establish lifelong latent 
infection in the host, mainly in macrophages and 
hematopoietic stem cells/progenitors (then passively 
transmitted to the mature myeloid progenies), and is a 
recognized cause of mononucleosis-like syndromes.36 
(Table 1) 
 
Large granular lymphocyte proliferation. In contrast to 
HHV-6, HCMV has not been proven to be involved in 
human cancer. However, Rodriguez-Caballero and 
colleagues37 suggested a role of HCMV in the 
pathogenesis of a specific subtype of large granular 
lymphocyte (LGL) proliferation involving CD4+/CD8+/-
dim
 T cells. In particular, they used microarray gene 
expression profile (GEP) to show that CD4+ T cells in 
patients with CD4+ LGL expansions, differ 
significantly from HCMV-specific memory CD4+ 
lymphocytes derived from healthy control individuals. 
The chronic antigenic stimulation of T cells by HCMV 
can lead to persistent monoclonal expansion of 
vβ13.1/CD4+ NKa+ CD8dim+ lymphocytes presenting a 
deregulation of genes involved in cell cycle 
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progression, resistance to apoptosis and genetic 
instability. The observed deregulation of key genes 
allows these cells to accumulate in excess to what is 
required to control HCMV infection and to abnormally 
proliferate. (Table 1) 
 
γ HERPESVIRUSES 
HHV-8. Epidemiology and biology. Human 
herpesvirus-8 (HHV-8) was identified by Moore & 
Chang in 1994, from the Kaposi’s sarcoma (KS) tissues 
of patients with AIDS. HHV-8 is not ubiquitous in the 
general population: the infectious rates are low in the 
United Kingdom, United States and Asia, intermediate 
in Mediterranean countries and high in Central Africa. 
The seroprevalence of HHV-8 among blood donors 
ranges from 0.2% in Japan, to up to 10% in the United 
States, and to more than 50% in Africa,38 with rates in 
Italy and other Mediterranean countries falling between 
these percentages.39,40 HHV-8 is mainly spread by 
sexual route in non-endemic areas, while non-sexual 
transmission may be important in endemic areas where 
infection is usually acquired early in the childhood.  
HHV-8 is classified as a γ-herpesvirus, related to 
EBV and Herpesvirus Saimiri. Like other 
herpesviruses, HHV-8 is a large, double-stranded DNA 
virus that replicates in the nucleus as a closer circular 
episome during latency, but linearizes during virion 
packaging and replication. The HHV-8 genome 
typically contains genes that are homologous to cellular 
genes involved in the control of cell cycle and 
apoptosis. Similarly to other herpesviruses, HHV-8 has 
evolved to persist within the lymphoid system and has 
shown an oncogenic potential. HHV-8 infection has 
been described in association with rare 
lymphoproliferative disorders, including primary 
effusion lymphoma (PEL), multicentric Castleman’s 
disease (MCD), and MCD-associated plasmablastic 
lymphoma, often occurring in AIDS patients. A subset 
of viral proteins is expressed in HHV-8-associated 
lymphoproliferative disorders and are involved in the 
viral lymphomagenesis. The viral proteins expressed in 
most PEL cells are the following: latency-associated 
nuclear antigen 1 (LANA -1), v-Cyclin, v-FLICE 
inhibitory protein (v-FLIP), v-interferon regulatory 
factor/LANA-2, Kaposin, v-Interleukein-6 (v-IL-6). 
LANA-1, v-Cyclin, v-FLIP and v-IL-6 are also 
expressed in most of the MCD cases. Two additional 
proteins, namely the K1 and the v-G-protein-coupled 
receptor (v-GPCR) are expressed in few cases of PEL 
and MCD.41 (Table 1) 
 
Primary Effusion Lymphoma. PEL has been included 
in the WHO classification as a distinct entity among 
AIDS-associated NHLs, representing about 3-4% of all 
AIDS-NHLs.42-44 The lymphoma grows predominantly 
in serous effusions, without solid tumor masses in the 
affected body cavity,45-47 while involvement of lymph 
nodes,48 bone marrow49,50 or other tissues51 is 
occasionally seen. A number of continuous cell lines 
has been established from such lymphomatous 
effusions and peripheral blood of PEL patients.52 The 
PEL cells can include features of large cell 
immunoblastic and anaplastic lymphoma,53 and also 
sometimes express a more plasmacytoid cytology.42 
PEL cells generally lack immunophenotypical 
expression of differentiated B- or T- cell antigens, but 
for MUM1 and CD138, reflecting their post-germinal 
centre B-cell origin. Consistent with this, the gene 
expression profile analysis suggests a plasmablastic 
derivation of PEL cells.54,55 They express cell 
activation associated markers, including HLA-DR, 
CD23, CD25, CD30 and CD38, and the epithelial 
membrane antigen whereas adhesion markers are 
variably expressed.43,52 The B cell lineage derivation of 
PEL cells is established on the basis of clonal 
rearrangements of the heavy immunoglobulin (Ig) 
genes,45,52 and the PCR-based findings of a preferential 
expression of certain lambda light chain genes in 
AIDS-related PELs, suggesting clonal proliferation by 
an antigen selection process.56 A few cases of AIDS-
related PEL did not demonstrate Ig gene 
rearrangements, consistent with a polyclonal pattern of 
lymphoproliferation.47 In contrast to other non 
Hodgkin’s B-cell lymphoma types, neither c-MYC nor 
other proto-oncogene rearrangements were detected in 
PELs.54 Likewise, a wild type of the tumor suppressor 
p53 gene is expressed by PELs, while mutations of the 
BCL-6 5’ non-coding regions have been documented in 
most of the cases.52 PELs show complex karyotypes, 
the most frequent chromosomal abnormalities being 
trisomy 7, 12 and aberrations of chromosomal bands 
1q21-q25.52 Virtually all reported cases of PEL have a 
relatively high number of HHV-8 DNA copies (40-
150) per cell, most cells being latently infected and 
relatively few permissive for lytic infection as obtained 
in cultured PEL lines. Analysis of HHV-8 terminal 
repeats (TR) by pulsed-field gel electrophoresis has 
shown monoclonal or oligoclonal fused TR fragments 
in all examined cases of PEL, suggesting HHV-8 
infection of clonogenic cells, supporting an etiologic 
role of the virus in these lymphoproliferations.57 EBV 
co-infection is detected in many cases of PEL, also 
with a monoclonal infection pattern and with a 
restricted antigen expression pattern of latency. Human 
interleukin-6 (IL-6) and -10 (IL-10), v-IL-6 and 
vascular endothelial growth factor (VEGF) are the 
major growth factors released and used by PEL cells 
for autocrine growth stimulation.52,58-60 The occurrence 
of PEL in a non-AIDS setting appears to be very rare 
and has been reported in very few cases of solid organ 
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transplant patients,50,61,62 and a few cases have also 
been described in HIV negative elderly men, most of 
them originating from HHV-8 endemic areas.63,64 The 
clinical outcome of AIDS-related and post-transplant 
PEL is very poor, with a median survival from 2 to 6 
months, despite chemotherapy.50,52,57 Decreasing CD4+ 
cell counts seem to be the most important indicator of 
progression of AIDS-related PEL.65 In HIV negative 
patients, PEL may have a more indolent clinical course 
without specific therapy and may initially respond to 
drainage procedures.63 Recently, it has been reported 
that azidothymidine and interferon-α induce apoptosis 
in PEL cells either in vitro or in vivo,66,67 and PEL 
remission was observed in a patient on anti-retroviral 
therapy.68 We have demonstrated that cidofovir at high 
doses induces in vitro apoptosis in PEL cell lines and 
PEL remission in four HIV negative, elderly Italian 
men treated with intrapleural/intraperitoneal injections 
of cidofovir, who had recurrent effusions not 
responding either to pleural/peritoneal drainages or to 
chemotherapy.69,70 Recent in vitro data have shown that 
glycyrrhizic acid, contained in the licorice root, induces 
apoptosis of PEL cells, by down-regulating the 
synthesis of the HHV-8 LANA-1.71 Other approaches 
have recently been considered for the treatment of 
PEL, based on the targeting of viral gene products,72,73 
providing the basis for new therapeutic options for PEL 
patients who are generally poor candidates for 
aggressive chemotherapy.  
 
Multicentric Castleman’s Disease (MCD) and MCD-
associated plasmablastic lymphoma. MCD of plasma 
cell type is an atypical lymphoproliferative disorder, 
which is histologically characterized by abundance and 
prominent alterations of the germinal centers, marked 
plasmacytic infiltration, and vascular hyperplasia.74 
Two types of malignancies, lymphoma and KS, have 
been reported to occur during the course of MCD in 
18% and 13% of cases respectively.74 HHV-8 DNA 
sequences have been detected in most of MCD cases 
occurring in HIV positive patients, but only in few HIV 
negative cases.75-78 HHV-8 infection is also found in 
most MCD patients with associated POEMS 
(polyneuropathy, organomegaly, endocrinopathy, M 
protein, skin changes) syndrome.79 One case of HHV-8 
positive MCD has also been reported in a renal 
transplant patient with KS.80 HHV-8 positive MCD 
cells, expressing LANA-1, morphologically resemble 
plasmablasts and are localized in the mantle zone of the 
follicles.81 These plasmablasts show λ light-chain 
restriction and coalesce to form microscopic 
lymphomas in some MCD cases, which could herald 
the development of frank HHV-8 positive 
plasmablastic lymphoma.82-84 A role in the 
pathogenesis of MCD for an over-expression of IL-6, a 
cytokine which promotes B cell survival and 
proliferation, has been proposed.74 The expression of v-
IL-6 in a proportion of HHV-8 infected MCD cells85-88 
thus appears to support such a pathogenic mechanism. 
This is consistent with findings that exacerbations of 
systemic symptoms in MCD correlate with an increase 
in HHV-8 viral load together with IL-6 and IL-10, 
which thus represent markers of disease activity.89,90 
Recent studies suggest that HHV-8 positive MCD 
cases have a more aggressive clinical course and a 
poorer prognosis.82 With regard to therapy, single agent 
chemotherapy with vinblastine is the most effective 
therapeutic option and may prolong survival.91 A 
patient with MCD has successfully been treated with 
retinoic acid and prednisone.92 Ganciclovir has also 
been effective in attenuating the constitutional 
symptoms in some cases of HIV-associated HHV-8 
positive MCD cases.93 Recently, treatment of MCD 
with humanized anti-IL-6 receptor antibody has been 
reported to be safe and to alleviate chronic 
inflammatory symptoms and wasting in a series of 28 
patients, followed-up for 60 weeks.94 
 
Other diseases. The pathogenetic association between 
HHV-8 infection and the development of multiple 
myeloma, proposed by Rettig and colleagues,95 has not 
been confirmed.96-98 HHV-8 infection is certainly rare 
in lymphoproliferative diseases other than PEL or 
MCD, both in HIV positive and HIV negative subjects. 
Moreover, the occurrence of HHV-8 positive solid 
lymphomas, usually extranodal and extracavitary, but 
with pathobiological features mimicking those of PEL, 
has been described in AIDS as well as in HIV negative 
patients.99 HHV-8 infection was documented in 
association with hepatitis C virus infection in one case 
of plasma cell leukemia,100 and three HIV negative 
cases of a germinotropic lymphoproliferative disorder 
characterized by plasmablasts coinfected by HHV-8 
and EBV have also been described.101 HHV-8 DNA 
and LANA-1 antigens have been detected in liver, lung 
and bone marrow tissues from patients affected with 
common variable immunodeficiency and 
granulomatous/lymphocytic interstitial lung disease, 
suggesting a pathogenetic viral role in this disorder.102 
HHV-8 DNA was also found in a single case of 
primary cerebral lymphoma, in a woman who had 
received long-term steroid therapy for uveitis, 
suggesting that HHV-8 infection may be occasionally 
involved in a lymphoproliferation process associated 
with iatrogenic immunesuppression.103 Consistent with 
this, the occurrence of an EBV negative, HHV-8 
positive, monoclonal, lymphoproliferative disease of 
polymorphic type has recently been reported in a 
HHV-8 seronegative Jewish man, nine months after 
receiving a kidney from his HHV-8 seropositive
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Table 1. Main biological, epidemiological and hematologic features of human β-herpesviruses and HHV-8 infections. 
 
Herpes 
Virus 
 
Tropism 
 
Epidemiology 
 
Non-neoplastic 
hematologic 
manifestations 
 
Associations with 
neoplastic diseases 
HHV-6 
Peripheral blood mononuclear 
cells (mainly  T lymphocytes 
and monocytes); hematopoietic 
progenitor cells; neuroglial 
cells; salivary gland epithelial 
cells. Lifelong persistence also 
as chromosomal genome 
integration. 
Worldwide diffusion (variants 
A and B, with 90% nucleotide 
identity), infection early in life. 
Transmission: saliva, in utero, 
blood, organ transplant. 
 
Mononucleosis-like 
syndrome, reactive 
lymphadenopathies, 
hemophagocytic syndrome, 
pancytopenias.  
Possible role in Rosai 
Dorfman Disease. 
Possible role in 
Angioimmunoblastic T-
cell Lymphoma and in 
Hodgkin’s disease. 
HCMV 
Hematopoietic progenitor cells 
(mainly monocyte-
macrophages); peripheral blood 
mononuclear cells; endothelial 
cells and fibroblasts. 
Worldwide diffusion, 
seropositivity increasing with 
age (98% over 50 years old). 
Transmission: saliva, in utero, 
sexual route, blood, organ 
transplant. 
Mononucleosis-like 
syndrome, hemophagocytic 
syndrome, pancytopenias. 
Possible role in Large 
Granular Lymphocyte 
lymphocytosis. 
HHV-8 
B-lymphocytes; hematopoietic 
progenitors cells; microvascular 
endothelial cells (lymphatic and 
blood vascular cells). 
 
Not ubiquitary diffusion: 
seroprevalence 30-70% in 
endemic African areas, 10-25% 
in Mediterranean areas. 
Transmission: vertical in 
endemic areas, sexual in non-
endemic areas; organ transplant, 
blood? 
Reactive 
lymphadenopathies, 
hemophagocytic syndrome, 
pancytopenias, bone 
marrow aplasia in organ 
transplant patients. 
Kaposi’s Sarcoma, 
Primary Effusion 
Lymphoma, Multicentric 
Castleman’s 
Disease/plasmablastic 
lymphoma. 
 
father.104 Non malignant plasmacytic proliferations 
have also been reported in two solid organ transplant 
patients105 as well as in a few Italian cases of HIV 
negative angioimmunoblastic lymphadenopathy.106 
Interestingly, a few cases of benign lymphadenopathy 
with germinal center hyperplasia and increased 
vascularity in which HHV-8 DNA sequences were 
detected, have been reported in HIV negative75,106 and 
HIV positive106,107 young adults. The only one case of 
well documented HHV-8 primary infection in HIV 
positive subjects has been reported to be associated 
with the development of fever, splenomegaly and a 
cervical lymphadenopathy, characterized by 
angiolymphoid hyperplasia.108 Thus, the above 
mentioned histologic features of florid follicular 
hyperplasia and increased vascularity, which are 
observed also in MCD, are likely to represent the 
distinct histologic pattern of lymphoid response 
induced by HHV-8. Interestingly, a 
lymphoproliferative disease characterized by persistent 
angiofollicular lymphadenopathy is induced in simian 
immunodeficiency-virus infected Rhesus Macaques, 
following infection with the simian homologue of 
HHV-8.109  
It is also likely that, as with other human 
herpesviruses, a HHV-8 primary infection or 
reactivation, is manifested by non neoplastic 
pathological changes. Thus, HHV-8 DNA has been 
detected in the pathologic lung tissue of HIV negative 
and positive patients with interstitial pneumonitis.110,111 
Fever, cutaneous rash and hepatitis have also been 
reported in an Italian patient with NHL, who received 
autologous peripheral blood stem cell (PBSC) 
transplantation and showed HHV-8 reactivation.112 
Recently, we had also the possibility to study primary 
HHV-8 infection in two patients four months after 
kidney transplantation from the same HHV-8-
seropositive cadaveric donor. Seroconversion and 
viremia coincided with development of a disseminated 
KS in one patient and with an acute syndrome of fever, 
splenomegaly, cytopenia, and marrow failure with 
plasmacytosis in the other patient.113 We also reported 
a further case of HHV-8 reactivation associated with 
fever and marrow aplasia with plasmacytosis in a 
patient with NHL, after autologous PBSC 
transplantation. HHV-8 transcripts and latency 
associated nuclear antigen were expressed in the 
immature myeloid progenitors of the aplastic marrow 
of these patients.113 In recent studies we and others 
have observed that HHV-8 may also exert a 
myelosuppressive effect in vitro,114,115 suggesting that 
HHV-8 could also be implicated in the complex 
pathophysiology of cytopenias often occurring in HIV 
infected patients.116 (Table 1) 
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